

The Essential RBRVS

A comprehensive listing of RBRVS values for CPT[®] and HCPCS codes



A full suite of resources including the latest code set, mapping products, and expert training to help you make a smooth transition. www.optumcoding.com/ICD10

Contents

Getting Started with The Essential RBRVS	i
Introduction	Introduction–I
Development	
Features	
RBRVS Highlights	
How to Use This Book	
Medicare and RBRVS	Introduction–4
Private Sector Payers and RBRVS	
Capitated Contracts and RBRVS	
Determining a Gross Conversion Factor	
Determining a Frequency-Adjusted Conversion Factor Developing an RBRVS-Based	
Fee Schedule	Introduction–10
Productivity Analysis Using RBRVS	
Cost/Benefit Analysis	Introduction–13
RBRVS Terminology	
Description of Columns in RBRVS Table	e Introduction–17
Modifiers	Introduction–20
Medicare Conversion Factors & GPCIs	
GPCI Tables Calculating GPCI Adjusted	Conversion Factors–1
Calculating GPCI Adjusted Reimbursement Rate Anesthesia Conversion Factors by	Conversion Factors–2
Anesthesia Conversion Factors by Locality	
Anesthesia	Anesthesia–i
Calculations of Total Anesthesia Values	Anesthesia–iii
Anesthesia Values	Anesthesia–1
Surgery	Surgery–i
Surgery Values	• •

Radiology Radiology Values	
Pathology and Laboratory Pathology and Laboratory Values	
Medicine Medicine Values	
Evaluation and Management	
Category II Category II Values	• •
Category III Category III Values	
HCPCS HCPCS Values	
Appendix A Description of Columns in Appendix A	
Appendix B OPPS Cap on the Technical Component of Radiology Services 2016 OPPS TC Payment Amount Determining the Lower of the MPFS and OPPS Payment Rates for Diagnostic	Appendix B–1 Appendix B–1
Radiology Services Multiple Procedure Reduction Table Layout Diagnostic Imaging Family Indicator	Appendix B–2 Appendix B–3 Appendix B–3
Procedural Index	inaex–1

Introduction

Development

The Essential RBRVS incorporates the relative values produced by the Centers for Medicare and Medicaid Services (CMS) for the Medicare Physician Fee Schedule (MPFS) into a comprehensive reference of resource-based relative value scale (RBRVS) relative values.

Even though RBRVS was developed specifically for assigning reimbursement rates to Medicare services, over 75 percent of non-Medicare payers use Medicare RBRVS to establish fees or maximum allowables for physician services. This works well for those services assigned relative values by CMS for Medicare. However, because Medicare does not assign a value to all services, the MPFS has gaps. In order to create a complete RBRVS-based fee schedule, these gap services need to have relative values assigned.

The Essential RBRVS Gap Methodology

The gaps in *The Essential RBRVS* are created when the Medicare Physician Fee Schedule (MPFS) does not provide values for procedure or supply codes. The gaps are created using various methodologies depending on the code.

For most codes, gap relative values are calculated by using relative value information from the Optum Relative Value Scale and adjusted to a scale similar to the MPFS relative values (RBRVS). The Optum relative values are developed by and are proprietary to Optum. Optum relative values are assigned when Optum has an understanding of how the procedure is typically billed by the industry and how it relates to other procedures. Relative values are based on difficulty, time, work, risk, and resources. Relative values are established by Optum employees, including an Optum Medical Director, clinicians, certified procedural coders, and analysts. Optum also consults with a panel of outside physicians and dentists during the relative value development process for certain codes.

Because Optum relative values are on a different scale than RBRVS relative values, we develop ratios relating the RBRVS and Optum scales for approximately 250 code ranges (within the CPT[®], HCPCS, and CDT systems). These ratios are multiplied by the Optum relative value to create the gap value. If Optum does not assign a relative value to a code, a gap value is not calculated. An example of the methodology is as follows (numbers used are for example purposes only): Procedure code 15828 is not valued in the MPFS. Optum has a relative value of 185 for this procedure code. The calculated ratio of Optum to the MPFS relative value units for the range of codes that this procedure code falls in is .292. The gap value would be $185 \times .292 = 54.02$.

Codes that are valued by Medicare's Clinical Lab Fee Schedule (CLAB); Durable Medical Equipment, Prosthetics/ Orthotics, & Supplies Fee Schedule (DMEPOS); or the Medicare ASP (average sale price) drug pricing files are treated differently. For these codes, the dollar values (national limit in CLAB) are used and relative values are created by dividing the dollar amounts by the MPFS national conversion factor. The CLAB, DMEPOS, and ASP files used are the most recent available at the time of printing. These files may update throughout the year.

Note: Gap relative values should not be used to calculate a Medicare reimbursement rate. In addition, the gap work relative value should not be used to calculate the outpatient prospective payment system (OPPS) rate.

Features

The Essential RBRVS is the most comprehensive resourcebased relative value scale available. Here are *The Essential RBRVS* features:

- Physician services, including those not part of the MPFS.
- Clinical laboratory services.
- Level II codes, such as durable medical equipment (DME), medical and surgical supplies, and transportation.
- J codes (injectable drugs).
- Appendix A This table provides the information necessary to determine if Medicare allows or makes adjustments to payment for the following: PC/TC component, assistant-at-surgery, multiple procedures, bilateral procedures, co-surgery or team surgery. The preop, intraop, and postop splits, the endoscopic base code, as well as the indicator identifying the level of physician supervision of diagnostic tests, if any, are also listed in appendix A. The special payment rules for each are identified at the beginning of the table.
- Appendix B Payment for the technical component (TC) portion of a radiology service will be limited to the lesser of the Medicare Physician Fee Schedule (MPFS) amount or the Outpatient Prospective Payment System (OPPS) amount in 2016. This is referred to by CMS as

The Essential RBRVS

	Code	M S	Description	Work Value	Non- Fac PE	Fac PE p	Mal- practice	Non-Fac Total	Fac Total	Global	Gap OP
	65710	A	Keratoplasty (corneal transplant); anterior lamellar	14.45	15.92	15.92	1.07	31.44	31.44	090	
	65730	Α	penetrating (except in aphakia or pseudophakia)	16.35	17.29	17.29	1.21	34.85	34.85	090	
	65750	Α	penetrating (in aphakia)	16.90	16.89	16.89	1.25	35.04	35.04	090	
	65755	Α	penetrating (in pseudophakia)	16.79	16.82	16.82	1.24	34.85	34.85	090	
	65756	Α	endothelial	16.84	15.58	15.58	1.25	33.67	33.67	090	
+	65757	С	Backbench preparation of corneal endothelial allograft prior to transplantation (List separately in addition to code for primary procedure)	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ	
	65760	Ν	Keratomileusis	15.98	13.91	13.91	3.31	33.20	33.20	XXX	
	65765	Ν	Keratophakia	23.17	20.17	20.17	4.80	48.14	48.14	XXX	
	65767	Ν	Epikeratoplasty	21.57	18.78	18.78	4.47	44.82	44.82	XXX	
	65770	Α	Keratoprosthesis	19.74	18.69	18.69	1.45	39.88	39.88	090	
	65771	Ν	Radial keratotomy	8.79	7.65	7.65	1.82	18.26	18.26	XXX	
	65772		Corneal relaxing incision for correction of surgically induced astigmatism	5.09	7.32	6.09	0.37	12.78	11.55	090	
	65775		Corneal wedge resection for correction of surgically induced astigmatism	6.91	8.24	8.24	0.50	15.65	15.65	090	
	65778		Placement of amniotic membrane on the ocular surface; without sutures	1.00	39.52	0.60	0.07	40.59	1.67	000	
	65779	Α	0,	2.50	31.41	1.65	0.18	34.09	4.33	000	
	65780		Ocular surface reconstruction; amniotic membrane transplantation, multiple layers	7.81	11.96	11.96	0.57	20.34	20.34	090	
	65781	A	or living donor)	18.14		18.40	1.34	37.88	37.88	090	
	65782	A	obtaining graft)	15.43	16.10	16.10	1.15	32.68	32.68	090	
	65785		Implantation of intrastromal corneal ring segments	5.39	53.80	4.91	0.75	59.94	11.05	090	
	65800 65810	A	Paracentesis of anterior chamber of eye (separate procedure); with removal of aqueous with removal of vitreous and/or discission	1.53 5.82	1.74 6.97	0.96 6.97	0.11 0.43	3.38 13.22	2.60 13.22	000	
			of anterior hyaloid membrane, with or without air injection								
	65815	A	with removal of blood, with or without irrigation and/or air injection	6.00	11.64	7.12	0.44	18.08	13.56		
63	65820		Goniotomy	8.91	11.69	11.69	0.65	21.25	21.25	090	
	65850		Trabeculotomy ab externo	11.39	11.61	11.61	0.84	23.84	23.84		
•	65855		Trabeculoplasty by laser surgery	2.66	4.88	3.95	0.19	7.73	6.80	010	
	65860		Severing adhesions of anterior segment, laser technique (separate procedure)	3.59	4.90	3.34	0.26	8.75	7.19	090	
	65865	А	Severing adhesions of anterior segment of eye, incisional technique (with or without injection of air or liquid) (separate procedure); goniosynechiae	5.77	7.23	7.23	0.42	13.42	13.42		
	65870	Α	anterior synechiae, except goniosynechiae	7.39	8.85	8.85	0.54	16.78	16.78	090	
	65875	Α		7.81	9.51	9.51	0.57	17.89	17.89	090	
	65880	Α		8.36	9.82	9.82	0.62	18.80	18.80		
	65900		Removal of epithelial downgrowth, anterior chamber of eye	12.51	13.82	13.82	0.91	27.24	27.24		
	65920		Removal of implanted material, anterior segment of eye	9.99	11.67	11.67	0.74	22.40	22.40		
	65930		Removal of blood clot, anterior segment of eye	8.39	9.10	9.10	0.61	18.10	18.10		
	66020		Injection, anterior chamber of eye (separate procedure); air or liquid	1.64	3.52	1.98	0.12	5.28	3.74	010	
	66030	Α	medication	1.30	3.29	1.75	0.10	4.69	3.15	010	

+ Add-on • • Moderate Sedation

© AMA Mod 51 Exempt ③ Optum360 Modifier 51 Exempt CPT © 2015 American Medical Association. All Rights Reserved.

Code	M S	Description	Work Value	Non- Fac PE	Fac PE	Mal- practice	Non-Fac Total	Fac Total	Global Gap
88166	X		0.00	0.40	0.40	0.00	0.40	0.40	XXX
	26	rescreening under physician supervision	0.00	0.00	0.00	0.00	0.00	0.00	XXX
	TC		0.00	0.40	0.40	0.00	0.40	0.40	XXX
88167	X	with manual screening and computer-assisted	0.00	0.40	0.40	0.00	0.40	0.40	XXX
	26 TC	rescreening using cell selection and review under physician supervision	$\begin{array}{c} 0.00\\ 0.00\end{array}$	$\begin{array}{c} 0.00\\ 0.40\end{array}$	$\begin{array}{c} 0.00\\ 0.40\end{array}$	$\begin{array}{c} 0.00\\ 0.00\end{array}$	$\begin{array}{c} 0.00\\ 0.40\end{array}$	$\begin{array}{c} 0.00\\ 0.40\end{array}$	XXX IXXX
88172	A		0.69	0.40	0.40	0.00	1.62	1.62	XXX
001/2		immediate cytohistologic study to determine	0.69	0.35	0.35	0.02	1.02	1.02	XXX
	TC A	adequacy for diagnosis, first evaluation episode, each site	0.00	0.55	0.55	0.01	0.56	0.56	XXX
88173	Α	interpretation and report	1.39	2.90	2.90	0.05	4.34	4.34	XXX
	26 A		1.39	0.65	0.65	0.03	2.07	2.07	XXX
	TC A		0.00	2.25	2.25	0.02	2.27	2.27	XXX
88174	X		0.00	0.81	0.81	0.00	0.81	0.81	XXX
	26 TC	system), collected in preservative fluid, automated thin layer preparation; screening by automated	$\begin{array}{c} 0.00\\ 0.00\end{array}$	0.00 0.81	0.00 0.81	$\begin{array}{c} 0.00\\ 0.00\end{array}$	$\begin{array}{c} 0.00\\ 0.81 \end{array}$	$\begin{array}{c} 0.00\\ 0.81 \end{array}$	XXX IXXX
00175		system, under physician supervision							
88175	X 26	with screening by automated system and manual rescreening or review, under	$\begin{array}{c} 0.00\\ 0.00\end{array}$	1.01 0.00	1.01 0.00	$\begin{array}{c} 0.00\\ 0.00\end{array}$	$\begin{array}{c} 1.01 \\ 0.00 \end{array}$	$\begin{array}{c} 1.01 \\ 0.00 \end{array}$	XXX IXXX
	TC	physician supervision	0.00	1.01	1.01	0.00	1.01	1.01	XXX
88177	A		0.42	0.42	0.42	0.00	0.85	0.85	ZZZ
001//		immediate cytohistologic study to determine	0.42	0.21	0.21	0.01	0.64	0.64	ZZZ
	TC A		0.00	0.21	0.21	0.00	0.21	0.21	ZZZ
		evaluation episode, same site (List separately in addition to code for primary procedure)							
88182	Α	Flow cytometry, cell cycle or DNA analysis	0.77	2.36	2.36	0.04	3.17	3.17	XXX
	26 A		0.77	0.27	0.27	0.01	1.05	1.05	XXX
	TC A		0.00	2.09	2.09	0.03	2.12	2.12	XXX
88184	Α	Flow cytometry, cell surface, cytoplasmic, or	0.00	2.12	2.12	0.01	2.13	2.13	XXX
	26	nuclear marker, technical component only; first	0.00	0.00	0.00	0.00	0.00	0.00	XXX 🔳
	TC	marker	0.00	2.12	2.12	0.01	2.13	2.13	XXX 🔳
88185	A	each additional marker (List separately in	0.00	1.29	1.29	0.00	1.29	1.29	ZZZ
	26 TC	addition to code for first marker)	0.00	0.00 1.29	$0.00 \\ 1.29$	$\begin{array}{c} 0.00\\ 0.00\end{array}$	0.00 1.29	0.00 1.29	ZZZ ■ ZZZ ■
88187		Flow cytometry, interpretation; 2 to 8 markers	1.36	0.61	0.61	0.00	2.04	2.04	XXX
88188	A	9 to 15 markers	1.69	0.81	0.81	0.07	2.59	2.59	XXX
88189	A	16 or more markers	2.23	0.81	0.81	0.09	3.19	3.19	XXX
								0.00	XXX
88199	26 C	Unlisted cytopathology procedure	$\begin{array}{c} 0.00\\ 0.00\end{array}$	0.00 0.00	XXX				
	TC C		0.00	0.00	0.00	0.00	0.00	0.00	XXX
88230	X	Tissue culture for non-neoplastic disorders;	0.00	4.43	4.43	0.00	4.43	4.43	XXX 🔳
	26	lymphocyte	0.00	0.00	0.00	0.00	0.00	0.00	XXX
	TC		0.00	4.43	4.43	0.00	4.43	4.43	XXX
88233	X	skin or other solid tissue biopsy	0.00	5.35	5.35	0.00	5.35	5.35	XXX 🔳
	26		0.00	0.00	0.00	0.00	0.00	0.00	XXX
	TC		0.00	5.35	5.35	0.00	5.35	5.35	XXX 🔳
88235	X	amniotic fluid or chorionic villus cells	0.00	5.60	5.60	0.00	5.60	5.60	XXX
	26 TC		$\begin{array}{c} 0.00\\ 0.00\end{array}$	0.00 5.60	0.00 5.60	$\begin{array}{c} 0.00\\ 0.00\end{array}$	0.00 5.60	0.00 5.60	XXX XXX
88237	X	Tissue culture for neoplastic disorders; bone	0.00	4.80	4.80	0.00	4.80	4.80	
0023/	26 ^A	marrow, blood cells	0.00	4.80	4.80	0.00	4.80 0.00	$4.80 \\ 0.00$	XXX XXX
	TC		0.00	4.80	4.80	0.00	4.80	4.80	XXX
88239	X	solid tumor	0.00	5.61	5.61	0.00	5.61	5.61	XXX
	26	·····	0.00	0.00	0.00	0.00	0.00	0.00	XXX
	TC		0.00	5.61	5.61	0.00	5.61	5.61	XXX
88240	X	Cryopreservation, freezing and storage of cells,	0.00	0.38	0.38	0.00	0.38	0.38	XXX 🗖
	26	each cell line	0.00	0.00	0.00	0.00	0.00	0.00	XXX 🗖
	TC		0.00	0.38	0.38	0.00	0.38	0.38	XXX 🔳

A Revised Code